What question did this study set out to answer?

To evaluate the long-term benefits of the mRNA-based neoantigen vaccine in preventing melanoma recurrence or death.

February 5, 2026

Personalized Cancer Vaccine Shows Durable Benefit at 5 Years

Key Points

To evaluate the long-term benefits of the mRNA-based neoantigen vaccine in preventing melanoma recurrence or death.
Conducted a phase IIb trial (KEYNOTE-942)
Administered intismeran autogene with pembrolizumab
Followed participants for five years to assess outcomes
Reduced risk of melanoma recurrence or death by approximately 49%
Demonstrated durable benefits over a five-year period
Supports the use of personalized vaccine strategies in cancer treatment

Abstract

Five-year data from the phase IIb KEYNOTE-942 study show that the mRNA-based neoantigen vaccine intismeran autogene continues to reduce the risk of melanoma recurrence or death by roughly 49% when combined with pembrolizumab. This durability strengthens confidence in the personalized vaccine strategy, but a larger phase III trial will provide the decisive findings.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Cancer Discovery

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Personalized Cancer Vaccine Shows Durable Benefit at 5 Years

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider